Moni Miyashita has served on the Halozyme Therapeutics Board of Directors since 2022 and is a member of the Nominating and Corporate Governance Committee. She brings over 25 years of global experience leading business transformations and building new businesses through strategy, new business models and mergers and acquisitions.
From 2019 to 2024, Ms. Miyashita served as Executive Vice President and Chief Strategy Officer of Valo Health, LLC, a technology company built to transform the drug discovery and development process using human-centric data and artificial intelligence computation. From August 2015 to May 2019 she was a Partner at Innosight, providing growth strategy consulting to businesses in the biotech, healthcare and technology industries, and from 2011 to 2015 she served as a Senior Advisor at McKinsey & Company, advising senior executive leadership teams on executing strategic M&A. Earlier, she served as Vice President, Corporate Development at IBM Corporation from 1998 to 2011.
She received her B.S. in marketing from the University of Colorado and her M.B.A. from the University of Denver. She is not standing for re-election at the 2026 Annual Meeting, and her term will expire as of the date of that meeting.